WHAT IS CLAIMED IS:

1. A formulation comprising:

(i) about 10 mg/ml to about 200 mg/ml of an anti-TIGIT antibody, or antigen binding fragment thereof;

(ii) about 5 mM to about 20 mM buffer;

(iii) about 6% to about 8% weight / volume (w/v) non-reducing sugar;

(iv) about 0.01 % to about 0.10% (w/v) non-ionic surfactant; and

(v) about 1 mM to about 20 mM anti-oxidant.

2. The formulation of claim 1, wherein the anti-TIGIT antibody or antigen binding fragment thereof comprises three light chains CDRs comprising CDRL1 of SEQ ID NO: 111, CDRL2 of SEQ ID NO: 112, CDRL3 of SEQ ID NO: 113 and three heavy chain CDRs comprising CDRH1 of SEQ ID NO: 108, CDRH2 of SEQ ID NO: 154, and CDRH3 of SEQ ID NO: 110.

3. The formulation of claim 1 or 2, wherein the anti-TIGIT antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising SEQ ID NO: 148 and a light chain variable region comprising SEQ ID NO: 152.

4. The formulation of claim 3, wherein the anti-TIGIT antibody comprises (i) a human heavy chain IgG1 constant domain comprising the amino acid sequence of SEQ ID NO:291 and a human kappa light chain constant domain comprising the amino acid sequence of SEQ ID NO:293; or (ii) a human heavy chain IgG4 constant domain comprising the amino acid sequence of SEQ ID NO:292 and a human kappa light chain constant domain comprising the amino acid sequence of SEQ ID NO:293.

5. The formulation of any one of claims 1-4, wherein the formulation has a pH between 5.3 and 6.2.

6. The formulation of any one of claims 1-5, wherein the buffer is a L-histidine buffer, the non-reducing sugar is sucrose, the non-ionic surfactant is polysorbate 80, and the anti-oxidant is L-methionine, the formulation comprising:

(i) about 10 mg/ml to about 200 mg/ml of an anti- TIGIT antibody, or antigen binding fragment thereof;
(ii) about 5 mM to about 20 mM of a L-histidine buffer;
(iii) about 6% to about 8% (w/v) sucrose;
(iv) about 0.01 % to about 0.10% (w/v) polysorbate 80; and
(v) about 1 mM to about 20 mM L-methionine.

7. The formulation of any of claims 1-6, comprising about 8mM to about 12 mM of L-histidine buffer.

8. The formulation of any of claims 6-7, comprising about 5mM to about 10mM L-methionine.

9. The formulation of any of claims 6-8, comprising polysorbate 80 at a weight ratio of about 0.02% w/v.

10. The formulation of any of claims 1-9, comprising about 10 mg/ml to about 100 mg/ml of the anti-TIGIT antibody or antigen binding fragment thereof.

11. The formulation of claim 10, wherein concentration of the anti- TIGIT antibody or antigen binding fragment thereof is about 10 mg/ml, 12.5 mg/ml, 25 mg/ml, 50 mg/ml, 75 mg/ml or 100 mg/ml.

12. The formulation of any of claims 1-11 comprising about 25 mg/mL of the anti-TIGIT antibody, 10 mM L-histidine buffer, about 7% w/v sucrose, about 0.02% polysorbate 80, and about 10 mM L-methionine.

13. The formulation of any of claims 1-11 comprising about 50 mg/mL of the anti-TIGIT antibody, 10 mM L-histidine buffer, about 7% w/v sucrose, about 0.02% polysorbate 80, and about 10 mM L-methionine.

14. The formulation of any of claims 1-11 comprising about 75 mg/mL of the anti-TIGIT antibody, 10 mM L-histidine buffer, about 7% w/v sucrose, about 0.02% polysorbate 80, and about 10 mM L-methionine.

15. The formulation of any of claims 1-11 comprising about 100 mg/mL of the anti-TIGIT antibody, 10 mM L-histidine buffer, about 7% w/v sucrose, about 0.02% polysorbate 80, and about 10 mM L-methionine.

16. The formulation of any of claims 1-15, wherein the formulation has a pH of about 5.5 – 6.3.

17. The formulation of claim 16, wherein the formulation has a pH of about 5.8-6.0.

18. The formulation of any of claims 1-17, further comprising an anti-PD1 antibody or antigen binding fragment thereof.

19. The formulation of claim18, wherein the anti-human PD-1 antibody or antigen binding fragment thereof comprises three light chain CDRs of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 and three heavy chain CDRs of SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

20. The formulation of any of claims 18-19, wherein the anti-human PD-1 antibody or antigen binding fragment thereof comprises a variable light region which comprises the amino acid sequence set forth in SEQ ID NO:4, and a variable heavy region which comprises the amino acid sequence set forth in SEQ ID NO:9.

21. The formulation of any of claims 16-19, wherein the formulation comprises an anti-human PD-1 antibody that is pembrolizumab.

22. The formulation of any of claims 18-21, wherein the ratio of the anti-PD1 antibody to the anti-TIGIT antibody is 1:1.

23. The formulation of any of claims 18-22, comprising about 20 mg/ml of the anti-PD1 antibody, about 20 mg/ml of the anti-TIGIT antibody, 10 mM L-histidine buffer, about 7% w/v sucrose, about 0.02% w/v polysorbate 80, and about 10 mM L-methionine.

24. The formulation of any of claims 1-23, further comprising a chelator.

25. The formulation of claim 24, wherein the chelator is DTPA.

26. The formulation of any of claims 1-25, wherein the formulation is contained in a glass vial or an injection device.

27. The formulation of any of claims 1-26 that is a liquid formulation, that is frozen to at least below -70° C, or is a reconstituted solution from a lyophilized formulation.

28. The formulation of any of claims 1-27, wherein after 12 months at 5°C:

(i) the % monomer of the anti-TIGIT antibody is ≥ 95% as determined by size exclusion chromatography;

(ii) the % heavy chain and light chain of the anti-TIGIT antibody is ≥ 90% as measured by reduced CE – SDS;

(iii) the % heavy chain and light chain of the anti-TIGIT antibody is ≥ 95% as measured reduced CE – SDS;

(iv) the % intact IgG of the anti-TIGIT antibody is ≥ 90% as measured by non-reduced CE-SDS; and/or

(v) % intact IgG of the anti-TIGIT antibody is ≥ 95% as measured by non-reduced CE-SDS.

29. A formulation of any of claims 1-28, for use as a medicament.

30. Use of the formulation of any of claims 1-28 for preparing a medicament for treating cancer or for treating chronic infection.